The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a more substantial loss in body weight and improve metabolic function, particularl